China Pharma (CPHI) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Intercure (INCR) has outperformed China Pharma (CPHI) over the past year, losing 37.5% versus a loss of 51.8%. Over five years, INCR leads with a -85.8% price change compared with -99.7% for CPHI. Intercure is the larger company by market cap ($75.5 million vs $41.3 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | INCR |
|---|---|---|
| Share price | $0.96 | $5.03 |
| Market cap | $41.30M | $75.47M |
| 1-day change | +12.94% | -1.95% |
| YTD return | -20.66% | +10.55% |
| 1-year return | -51.76% | -37.52% |
| 5-year return | -99.65% | -85.81% |
| EPS (TTM) | $-0.42 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $8.40 |
| 52-week low | $0.38 | $3.40 |
| Distance from 52-week high | -95.00% | -40.12% |
| Average volume | 5.81M | 21.73K |
| Shares outstanding | 43.02M | 15.00M |
| Employees | 215 | 285 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCR has outperformed CPHI by 14.2 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Healthcare · Drug Manufacturers - Specialty & Generic · 285 employees
CPHI vs INCR FAQ
Which is bigger, China Pharma or Intercure?
Intercure (INCR) is larger, with a market capitalization of $75.47M compared with $41.30M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or INCR?
INCR returned -37.52% over the past 12 months, compared with -51.76% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Intercure in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.